BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2030 related articles for article (PubMed ID: 10053096)

  • 1. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
    Wu M; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
    Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
    Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
    Bristow RE; Duska LR; Montz FJ
    Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.
    Bristow RE; Zerbe MJ; Rosenshein NB; Grumbine FC; Montz FJ
    Gynecol Oncol; 2000 Aug; 78(2):85-91. PubMed ID: 10926785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
    Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
    Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
    Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of surgical debulking on survival in stage IV ovarian cancer.
    Liu PC; Benjamin I; Morgan MA; King SA; Mikuta JJ; Rubin SC
    Gynecol Oncol; 1997 Jan; 64(1):4-8. PubMed ID: 8995539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent micropapillary serous ovarian carcinoma.
    Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
    Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytoreductive surgery in the management of stage IV epithelial ovarian cancer].
    Zang R; Zhang Z; Chen J
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):197-9. PubMed ID: 11776157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
    Lim MC; Kang S; Lee KS; Han SS; Park SJ; Seo SS; Park SY
    Gynecol Oncol; 2009 Jan; 112(1):28-34. PubMed ID: 19010521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.